Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

BACKGROUND: Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hypothesized that empaglifozin (EMPA) could modulate ectopic fat stores and myocardial energetics in high-fat-high-sucr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaborit, B., Ancel, P., Abdullah, A. E., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., Lasbleiz, A., Peiretti, F., Bornet, C. E., Lefur, Y., Pini, L., Rapacchi, S., Bernard, M., Resseguier, N., Darmon, P., Kober, F., Dutour, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919089/
https://www.ncbi.nlm.nih.gov/pubmed/33648515
http://dx.doi.org/10.1186/s12933-021-01237-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919089/
https://www.ncbi.nlm.nih.gov/pubmed/33648515
http://dx.doi.org/10.1186/s12933-021-01237-2

Ejemplares similares